Findings by Pradeep et al. imply that HER2-mediated activation of Notch-3 is necessary during the early steps of mammary tumorigenesis and targeted inhibition of these pathways can reduce early tumor progression in DCIS-HER2+ cancers with Notch-3 overexpression. Here, ERBB2 is linked to cancer.